Video | Business Headlines | Internet | Science | Scientific Ethics | Technology | Search

 


At Last There Is Something You Can Do About Flu

AT LAST THERE IS SOMETHING YOU CAN DO ABOUT FLU

You can toss away grandma's remedies, and forget about weeks in bed feeling ghastly. For the first time in 30 years, there's a new prescription medicine treatment for the dreaded flu, and it's a simple inhaler called Relenza that gets you back on your feet faster.

It's a common misconception that influenza is the same thing as a cold, only worse. In fact, the flu virus causes serious and potentially deadly respiratory illness. As the virus starts to copy itself and spread, and the body tries to fight it off, that's when all the other symptoms of headaches, muscle aches, fever and dehydration start.

"Relenza works by stopping the flu virus's copying mechanism," says Dr Ian Griffiths, medical director of Glaxo Wellcome, the maker of Relenza. "When the virus multiplies, it relies on an enzyme called neuraminidase to release the copies so that they can spread to new cells. Relenza blocks that releasing mechanism, stopping the infection from spreading.

"Trials in the US, Europe and Australia, where Relenza was invented by scientists from Biota Holdings Ltd, have shown that people recover up to 30 per cent faster with Relenza. At the same time, it minimises the severity of symptoms like headache, cough, sore throat, aching muscles and loss of appetite. This allows mothers, sports people, the self-employed and others who can't afford to have weeks in bed to get back on their feet more quickly.

"And because it's an inhaler, Relenza gets straight to the site of infection with no more side-effects than a sugar pill," Dr Griffiths says.

Influenza is expected to hit New Zealand hard this year. Influenza B has a three-to-five-year cycle and returns in 1999, while virologists also expect influenza A problems thanks to the return of the Sydney A strain which was responsible for over 3,000 deaths in the United Kingdom last northern winter. While vaccines have been made more widely available, and include Sydney A, they are ineffective against influenza B.

Symptoms of influenza include fever or feverishness (a temperature greater than 37.8 degrees celsius), headache, cough, muscle aches, sore throat and lack of energy.

Along with many other new medicines, Relenza is not government- subsidised, and will cost approximately $69.95 per treatment. However, Dr Griffiths many people may be willing to pay for something that gets them back working faster. Relenza is not available for children under 12 years old, and needs to be used within two days of the first signs of symptoms to be most effective.

ENDS....

MEDIA RELEASE FROM GLAXO WELLCOME NEW ZEALAND LTD.

References


1. Fleming D et al. `High risk' and otherwise healthy patients demonstrate alleviation of influenza symptoms 2.5 days earlier following inhaled zanamivir treatment; European Study, Winter 1997/8. 36th meeting of the IDSA, Denver, Colorado, USA, November 12-15, 1998; Abstract No: 789

2. Silagy CA et al. Impact of zanamivir on health status, productivity and health care resource use in patients with influenza. 36th meeting of the IDSA, Denver, Colorado, USA, November 12-15, 1998; Abstract No: 36

3. Silagy CA et al. On behalf of the MIST (Management of Influenza in the Southern Hemisphere Trialists) Study Group. Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. Lancet 1998; 352: 1877-81

4. Osterhaus A, et al. A double blind randomised trial of zanamivir in the treatment of acute influenza - clinical and virological efficacy results. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Diego, California, USA, September 24-27, 1998. Abstract.

5. Hayden FG et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza virus infection. N Engl J Med 1997; 337: 874-80

RELEASED VIA MEDIACOM

© Scoop Media

 
 
 
 
 
Business Headlines | Sci-Tech Headlines

 

Sky City : Auckland Convention Centre Cost Jumps By A Fifth

SkyCity Entertainment Group, the casino and hotel operator, is in talks with the government on how to fund the increased cost of as much as $130 million to build an international convention centre in downtown Auckland, with further gambling concessions ruled out. The Auckland-based company has increased its estimate to build the centre to between $470 million and $530 million as the construction boom across the country drives up building costs and design changes add to the bill.
More>>

ALSO:

RMTU: Mediation Between Lyttelton Port And Union Fails

The Rail and Maritime Union (RMTU) has opted to continue its overtime ban indefinitely after mediation with the Lyttelton Port of Christchurch (LPC) failed to progress collective bargaining. More>>

Earlier:

Science Policy: Callaghan, NSC Funding Knocked In Submissions

Callaghan Innovation, which was last year allocated a budget of $566 million over four years to dish out research and development grants, and the National Science Challenges attracted criticism in submissions on the government’s draft national statement of science investment, with science funding largely seen as too fragmented. More>>

ALSO:

Scoop Business: Spark, Voda And Telstra To Lay New Trans-Tasman Cable

Spark New Zealand and Vodafone, New Zealand’s two dominant telecommunications providers, in partnership with Australian provider Telstra, will spend US$70 million building a trans-Tasman submarine cable to bolster broadband traffic between the neighbouring countries and the rest of the world. More>>

ALSO:

More:

Statistics: Current Account Deficit Widens

New Zealand's annual current account deficit was $6.1 billion (2.6 percent of GDP) for the year ended September 2014. This compares with a deficit of $5.8 billion (2.5 percent of GDP) for the year ended June 2014. More>>

ALSO:

Still In The Red: NZ Govt Shunts Out Surplus To 2016

The New Zealand government has pushed out its targeted return to surplus for a year as falling dairy prices and a low inflation environment has kept a lid on its rising tax take, but is still dangling a possible tax cut in 2017, the next election year and promising to try and achieve the surplus pledge on which it campaigned for election in September. More>>

ALSO:

Job Insecurity: Time For Jobs That Count In The Meat Industry

“Meat Workers face it all”, says Graham Cooke, Meat Workers Union National Secretary. “Seasonal work, dangerous jobs, casual and zero hours contracts, and increasing pressure on workers to join non-union individual agreements. More>>

ALSO:

Get More From Scoop

 
 
Standards New Zealand

Standards New Zealand
 
 
 
 
 
 
 
 
Sci-Tech
Search Scoop  
 
 
Powered by Vodafone
NZ independent news